Apollomics - Class A opened lower at $18.11, compared with its previous close of $18.60. In the last trading session, the stock traded between $16.83 and $18.60. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 4 years ago in Apollomics - Class A is now worth
$ 0.58
Resulting in a loss of
$ 99.42 (99.42%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-1.62 (-8.70%)
Day High
$18.60
Day Low
$16.83
Day Open
$18.11
Prev Close
$18.60
Volume
10,466
1W Return
-9.28%
1M Return
-22.30%
3M Return
-8.17%
6M Return
15.92%
1Y Return
10.92%
Fundamentals
Market Cap ($ Mn)
50
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-491.08%
EPS (TTM)
-
Investment Returns
1 Week
-9.28%
1 Month
-22.30%
3 Months
-8.17%
6 Months
15.92%
9 Months
-15.05%
Financials
Quarterly
All values in $ Mn
No data available.
Updates
10Nov
Apollomics Latest Results: Loss per share narrows 64% YoY
Apollomics Inc reported a loss of $(4.06) per share for the first half. Losses narrowed by 64.29% compared to $(11.37) in the same period last year. The per-share deficit decreased significantly from the prior year baseline.
3 days ago
12Aug
Apollomics raises $10 million via private placement and note conversion
Apollomics Inc. announces a $10.0 million capital raise combining $8.0 million in cash equity at $15.00/share and a $2.0 million debt conversion by CEO Howard Chen at $12.00/share. The funds support Phase 2 trials for its lead oncology program, vebreltinib.
3mo ago
13Jul
Apollomics regains Nasdaq compliance on MVLS rule
Apollomics Inc. regained compliance with Nasdaq's MVLS requirement on July 8, 2026, after maintaining a market value of $35 million or greater for 10 consecutive business days, closing the compliance matter.
4mo ago
25Jun
Apollomics fails Nasdaq market value rule, regains Asia rights
Apollomics Inc. received a deficiency notice from The Nasdaq Stock Market LLC on June 18, 2026, for failing to maintain the minimum Market Value of Listed Securities of $35 million for 30 consecutive business days. The company has a 180-calendar-day compliance period expiring on December 15, 2026, to regain compliance by maintaining the threshold for 10 consecutive business days. Additionally, Apollomics terminated its Collaboration and License Agreement with Launxp International Co., Ltd. effective June 11, 2026, due to Launxp's failure to pay the remaining upfront balance of $3.8 million plus interest, thereby regaining rights to vebreltinib in Asia.
